Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAaron ChengJKJanet Kwiatkowski

Discussion

Loading...

Member takes

Overview

Observational analysis shows curative therapy improves ineffective erythropoiesis in beta-thalassemia, suggesting enhanced outcomes for patients.

Key Points

  • Elevated markers of ineffective erythropoiesis were found in the transfusion group, indicating poorer iron management.
  • Patients receiving curative therapy had normalized erythropoiesis and iron metabolism, demonstrating long-term benefits.
  • Statistical analysis revealed significant differences in erythropoietin and hepcidin across therapy types, supporting better treatment strategies.
  • Higher pre-transfusion hemoglobin goals may enhance management of ineffective erythropoiesis in beta-thalassemia patients.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfc1https://doi.org/10.1182/blood-2025-176
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biomarkers of ineffective erythropoiesis in patients with transfusion- dependent thalassemia2025
  2. 2Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion Burden2025
  3. 3Transfusion independence in thalassemia patients after failure of gene therapy or with hemoglobin h constant spring and hb e using luspatercept: A case series2025
  4. 4Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis2025
  5. 5Outcomes with luspatercept in patients with β-thalassemia: A systematic review and meta-analysis2025